<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01467882</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 8206-CPP-301</org_study_id>
    <nct_id>NCT01467882</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty</brief_title>
  <official_title>An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg
      6-month formulation in 44 patients suffering from central precocious puberty. The total study
      duration per patient will be 12 months (48 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children With LH Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 9 and 12</measure>
    <time_frame>at Months 1, 2, 3, 9 and 12</time_frame>
    <description>This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12</measure>
    <time_frame>from Month 6 to 12</time_frame>
    <description>This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children With LH Suppression (LH ≤ 4 IU/L)30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 6, 9 and 12</measure>
    <time_frame>at Months 1, 2, 3, 6, 9 and 12</time_frame>
    <description>This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children Maintaining LH Suppression at &lt;/= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12</measure>
    <time_frame>from Month 6 to 12</time_frame>
    <description>This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at Months 1, 2, 3, 6, 9, and 12</measure>
    <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estradiol Levels at Months 1, 2, 3, 6, 9, and 12</measure>
    <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</measure>
    <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children With Prepubertal Estradiol or Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</measure>
    <time_frame>at Months 1, 2, 3, 6, 9, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children Without Higher Basal LH and Estradiol or Testosterone</measure>
    <time_frame>at 2 days after second triptorelin injection (Day 171)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Height-for-age Z-score Per 2000 CDC Growth Charts at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Height-for-age Percentile Per 2000 CDC Growth Charts at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Growth Velocity at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Without Bone Age / Chronological Age Ratio Increase From Baseline at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Children Achieving Stabilization of Sexual Maturation at Months 6 and 12</measure>
    <time_frame>at Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Girls With Regression of Uterine Length Compared to Baseline at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Boys With Absence of Progression of Testis Volumes Compared to Baseline at Months 6 and 12</measure>
    <time_frame>Baseline to Months 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Central Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Triptorelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Powder and solution for solution for injection</description>
    <arm_group_label>Triptorelin</arm_group_label>
    <other_name>Trelstar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Onset of development of sex characteristics before 8 and 9 years in girls and boys,
             respectively (breast development in girls or testicular enlargement in boys according
             to the Tanner method), and candidate to receive at least 12 months of GnRH agonist
             therapy after study entry.

          2. Aged 2-8 years inclusive (i.e. &lt; 9 years) for girls and 2-9 years inclusive (i.e. &lt; 10
             years) for boys at initiation of triptorelin treatment.

          3. Initiation of triptorelin treatment at the latest 18 months after onset of the first
             signs of precocious puberty.

          4. Difference (Δ) bone age (Greulich and Pyle method) - chronological age ≥ 1 year.

          5. Pubertal-type LH response 30 minutes following a GnRH agonist stimulation test before
             treatment initiation (leuprolide acetate 20 μg/kg SC) ≥ 6 IU/L.

          6. Clinical evidence of puberty, defined as Tanner Staging ≥ 2 for breast development for
             girls and testicular volume ≥ 4 mL (cc) for boys.

          7. Informed consent signed by one parent or both parents (as per local requirements), by
             the liable parent or by the legal guardian (when applicable); assent signed by the
             child if ≥ 7 years.

        Non-inclusion criteria:

          1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of
             gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion.

          2. Non-progressing isolated premature thelarche.

          3. Presence of an unstable intracranial tumour or an intracranial tumour requiring
             neurosurgery or cerebral irradiation. Patients with hamartomas not requiring surgery
             are eligible.

          4. Evidence of renal (creatinine &gt; 2 x ULN) or hepatic impairment (bilirubin or ASAT &gt; 3
             x ULN).

          5. Any other condition or chronic illness or treatment possibly interfering with growth
             or other study endpoints (e.g. chronic steroid use [except mild topical steroids],
             renal failure, diabetes, moderate to severe scoliosis, previously treated intracranial
             tumour).

          6. Prior or current therapy with a GnRH agonist, medroxyprogesterone acetate, growth
             hormone or insulin-like growth factor-1 (IGF 1).

          7. Major medical or psychiatric illness that could interfere with study visits.

          8. Diagnosis of short stature, i.e. &gt; 2.25 SD below the mean height for age.

          9. Positive pregnancy test.

         10. Known hypersensibility to any of the test materials or related compounds.

         11. Use of anticoagulants (heparin and coumarin derivatives).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tala Dajani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Endocrinology of Phoenix, Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Reiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barry J. Reiner, MD, LLC, Baltimore, Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Galal Salem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SRCR, Inc, Bell Gardens, California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heidi Shea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine Associates of Dallas, Plano, Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Rappaport, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Endocrine Associates, Atlanta, Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Opada Alzohaili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alzohaili Medical Consultants, Dearborn, Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Quentin Van Meter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Meter Pediatric Endocrinology, Peachtree City, Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Domek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynn health Science Institute, Oklahoma City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Bethin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's &amp; Children's Hospital of Buffalo, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Kaplowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Medical Center, Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Medical Center, San Diego, California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Merritt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University, St. Louis, Missouri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Rose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Hospital, Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gad Kletter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Pediatric Specialist, Seattle, Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Aisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack university medical center, New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Barnabas Medical Center, Livingston, New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Rogers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goryeb Children's Hospital, Morristown, New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Children's Hospital, Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Gomez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, New Orleans, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Cassorla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IDIMI, Santiago, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arnold Palmer Pediatric Endocrinology Practice, Orlando, Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erica Eugster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Whitcomb Riley Hospital for Children, Indianapolis, Indiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar Flores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Monterrey, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nancy Wright MD P.A., Tallahasse, Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Endocrinology of Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Pediatric Endocrinology Practice</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy Wright MD P.A.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack university medical center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's &amp; Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Pediatric Specialist</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDIMI</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.debiopharm.com</url>
    <description>Study sponsor</description>
  </link>
  <reference>
    <citation>Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009 Apr;123(4):e752-62. doi: 10.1542/peds.2008-1783. Epub 2009 Mar 30. Review.</citation>
    <PMID>19332438</PMID>
  </reference>
  <reference>
    <citation>Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006 Aug;19(8):963-70.</citation>
    <PMID>16995580</PMID>
  </reference>
  <reference>
    <citation>Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: a single 30-minute post-stimulation LH sample is adequate. J Pediatr Endocrinol Metab. 2008 Dec;21(12):1113-8.</citation>
    <PMID>19189683</PMID>
  </reference>
  <reference>
    <citation>Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:723-37. Review.</citation>
    <PMID>10969915</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <results_first_submitted>June 25, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <disposition_first_submitted>August 19, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2014</disposition_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Intention to treat, defined as all participants enrolled</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Children</title>
          <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat, defined as all participants enrolled</population>
      <group_list>
        <group group_id="B1">
          <title>Children</title>
          <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.41" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6</title>
        <description>This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.</description>
        <time_frame>Month 6</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6</title>
          <description>This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.</description>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.18" lower_limit="81.34" upper_limit="98.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children With LH Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 9 and 12</title>
        <description>This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.</description>
        <time_frame>at Months 1, 2, 3, 9 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children With LH Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 9 and 12</title>
          <description>This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.</description>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12</title>
        <description>This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.</description>
        <time_frame>from Month 6 to 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12</title>
          <description>This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.</description>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children With LH Suppression (LH ≤ 4 IU/L)30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 6, 9 and 12</title>
        <description>This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.</description>
        <time_frame>at Months 1, 2, 3, 6, 9 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children With LH Suppression (LH ≤ 4 IU/L)30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 6, 9 and 12</title>
          <description>This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.</description>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children Maintaining LH Suppression at &lt;/= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12</title>
        <description>This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.</description>
        <time_frame>from Month 6 to 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children Maintaining LH Suppression at &lt;/= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12</title>
          <description>This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.</description>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at Months 1, 2, 3, 6, 9, and 12</title>
        <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>All Children Luteinizing Hormone</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
          <group group_id="O2">
            <title>All Children Follicle Stimulating Hormone</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at Months 1, 2, 3, 6, 9, and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.21" spread="20.28"/>
                    <measurement group_id="O2" value="-8.85" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.25" spread="20.41"/>
                    <measurement group_id="O2" value="-8.80" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.17" spread="20.53"/>
                    <measurement group_id="O2" value="-8.13" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.06" spread="22.17"/>
                    <measurement group_id="O2" value="-6.66" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.24" spread="20.49"/>
                    <measurement group_id="O2" value="-7.87" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.15" spread="20.50"/>
                    <measurement group_id="O2" value="-6.99" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estradiol Levels at Months 1, 2, 3, 6, 9, and 12</title>
        <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Intention to treat girls, defined as all girls enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Girls</title>
            <description>All girls enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estradiol Levels at Months 1, 2, 3, 6, 9, and 12</title>
          <population>Intention to treat girls, defined as all girls enrolled</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.87" spread="27.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.24" spread="31.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.15" spread="28.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.18" spread="31.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.08" spread="27.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.74" spread="28.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</title>
        <time_frame>Baseline to Months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Intention to treat boys, defined as all boys enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Boys</title>
            <description>All boys enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</title>
          <population>Intention to treat boys, defined as all boys enrolled</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-306.96" spread="184.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-290.70" spread="214.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-319.20" spread="177.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-317.62" spread="178.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-315.54" spread="183.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-301.86" spread="205.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children With Prepubertal Estradiol or Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</title>
        <time_frame>at Months 1, 2, 3, 6, 9, and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
          <group group_id="O2">
            <title>Girls</title>
            <description>All girls enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
          <group group_id="O3">
            <title>Boys</title>
            <description>All boys enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children With Prepubertal Estradiol or Testosterone Levels at Months 1, 2, 3, 6, 9, and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.36"/>
                    <measurement group_id="O2" value="87.18"/>
                    <measurement group_id="O3" value="80.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.37"/>
                    <measurement group_id="O2" value="89.47"/>
                    <measurement group_id="O3" value="80.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.18"/>
                    <measurement group_id="O2" value="92.31"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.82"/>
                    <measurement group_id="O2" value="79.49"/>
                    <measurement group_id="O3" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.82"/>
                    <measurement group_id="O2" value="82.05"/>
                    <measurement group_id="O3" value="80.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.55"/>
                    <measurement group_id="O2" value="79.49"/>
                    <measurement group_id="O3" value="80.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children Without Higher Basal LH and Estradiol or Testosterone</title>
        <time_frame>at 2 days after second triptorelin injection (Day 171)</time_frame>
        <population>AOC Subset is defined as 50% of the population randomly assigned</population>
        <group_list>
          <group group_id="O1">
            <title>AOC Subset</title>
            <description>All children in AOC subset who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children Without Higher Basal LH and Estradiol or Testosterone</title>
          <population>AOC Subset is defined as 50% of the population randomly assigned</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Height-for-age Z-score Per 2000 CDC Growth Charts at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height-for-age Z-score Per 2000 CDC Growth Charts at Months 6 and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Height-for-age Percentile Per 2000 CDC Growth Charts at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height-for-age Percentile Per 2000 CDC Growth Charts at Months 6 and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Growth Velocity at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Growth Velocity at Months 6 and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>cm/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Without Bone Age / Chronological Age Ratio Increase From Baseline at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Without Bone Age / Chronological Age Ratio Increase From Baseline at Months 6 and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Children Achieving Stabilization of Sexual Maturation at Months 6 and 12</title>
        <time_frame>at Months 6 and 12</time_frame>
        <population>Intention to treat, defined as all participants enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Children</title>
            <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Children Achieving Stabilization of Sexual Maturation at Months 6 and 12</title>
          <population>Intention to treat, defined as all participants enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Girls With Regression of Uterine Length Compared to Baseline at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat girls, defined as all girls enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Girls</title>
            <description>All girls enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Girls With Regression of Uterine Length Compared to Baseline at Months 6 and 12</title>
          <population>Intention to treat girls, defined as all girls enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Boys With Absence of Progression of Testis Volumes Compared to Baseline at Months 6 and 12</title>
        <time_frame>Baseline to Months 6 and 12</time_frame>
        <population>Intention to treat boys, defined as all boys enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Boys</title>
            <description>All boys enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Boys With Absence of Progression of Testis Volumes Compared to Baseline at Months 6 and 12</title>
          <population>Intention to treat boys, defined as all boys enrolled</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Children</title>
          <description>All children enrolled who received triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication or scientific communication related to this study can only take place once the agreement between the Sponsor and the Investigator has been reached.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eija Lundström</name_or_title>
      <organization>Debiopharm International, S.A.</organization>
      <phone>:+41 21 3210111</phone>
      <email>eija.lundstrom@debiopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

